Clinical Trial

HB1801 Combined Treatment of HER2-positive Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.
Trial Details
NCT Number NCT07116824
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions HER2-positive Breast Cancer
Enrollment 80 participants
Start Date 2025-09-15
Primary Completion 2026-07-15 (estimated)
Study Completion 2027-11-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-12